The South Korea government plans to improve the transparency and objectivity of standards for pharma firms to officially qualify as “innovative” and eligible for special policy treatment, amid foreign industry calls for improvement to the scheme.
There are also plans to ease the financial requirements for participation in state R&D projects to help ventures facing temporary financial difficulties.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?